CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

SAN CARLOS, Calif.--(BUSINESS WIRE)--Aug 5, 2026-

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug 4, 2026-

Gilead Sciences (NASDAQ:GILD) Issues Earnings Results, Beats Estimates By $0.51 EPS

Gilead Sciences (NASDAQ:GILD - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.26) by $0.51. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. During the same quarter in the prior year, the business earned $2.01 EPS. The business's quarterly revenue was up 10.6% compared to the same q…

Gilead second-quarter sales rise 8%, beating Wall Street estimates

By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of ​acquisitions. The company's ov...

Gilead reports strong Q2 driven by HIV portfolio

Gilead Sciences has reported strong second-quarter 2026 results, with total revenue increasing 10% year-on-year to $7.8bn.